Olympus Toekomstige groei

Future criteriumcontroles 3/6

Olympus zal naar verwachting groeien in winst en omzet met respectievelijk 14.4% en 5.1% per jaar. De winst per aandeel zal naar verwachting groeien met 16% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 16.1% zijn.

Belangrijke informatie

14.4%

Groei van de winst

16.0%

Groei van de winst per aandeel

Medical Equipment winstgroei	12.8%
Inkomstengroei	5.1%
Toekomstig rendement op eigen vermogen	16.1%
Dekking van analisten	Good
Laatst bijgewerkt	18 Nov 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

TSE:7733 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (JPY Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
3/31/2027	1,117,050	158,643	115,326	207,811	13
3/31/2026	1,055,588	142,517	106,331	192,771	14
3/31/2025	1,003,968	117,529	71,114	173,486	14
9/30/2024	973,595	87,726	81,759	147,854	N/A
6/30/2024	966,046	27,884	56,269	118,734	N/A
3/31/2024	936,210	26,610	-22,259	42,365	N/A
12/31/2023	916,092	39,468	-36,583	30,686	N/A
9/30/2023	901,507	56,534	11,195	80,406	N/A
6/30/2023	875,586	126,381	-1,680	72,238	N/A
3/31/2023	881,923	137,809	27,867	98,490	N/A
12/31/2022	933,645	137,623	45,131	109,416	N/A
9/30/2022	925,858	126,848	47,185	107,203	N/A
6/30/2022	891,410	121,912	60,183	119,188	N/A
3/31/2022	868,867	115,742	107,958	169,729	N/A
12/31/2021	793,727	95,274	85,693	150,356	N/A
9/30/2021	774,113	98,063	90,544	155,506	N/A
6/30/2021	785,411	84,467	78,484	139,415	N/A
3/31/2021	730,544	65,599	64,895	124,122	N/A
12/31/2020	715,924	46,443	55,563	116,827	N/A
9/30/2020	724,722	41,459	42,698	103,723	N/A
6/30/2020	752,176	42,855	50,303	113,526	N/A
3/31/2020	797,411	51,670	67,615	133,544	N/A
12/31/2019	807,887	60,758	72,843	136,095	N/A
9/30/2019	801,202	49,704	44,493	106,769	N/A
6/30/2019	795,193	33,469	8,586	70,321	N/A
3/31/2019	793,862	8,147	5,477	66,943	N/A
12/31/2018	795,479	15,554	9,623	71,514	N/A
9/30/2018	798,915	21,732	15,843	79,978	N/A
6/30/2018	795,205	30,324	N/A	100,036	N/A
3/31/2018	786,497	57,064	N/A	95,146	N/A
12/31/2017	786,608	85,083	N/A	N/A	N/A
9/30/2017	767,508	85,830	N/A	91,430	N/A
6/30/2017	751,458	79,716	N/A	N/A	N/A
3/31/2017	748,050	78,191	N/A	90,194	N/A
12/31/2016	745,543	60,888	N/A	N/A	N/A
9/30/2016	758,777	48,983	N/A	35,146	N/A
6/30/2016	785,444	54,390	N/A	N/A	N/A
3/31/2016	804,578	62,594	N/A	48,621	N/A
12/31/2015	807,197	2,188	N/A	N/A	N/A
9/30/2015	805,432	4,742	N/A	92,093	N/A
6/30/2015	785,230	-144	N/A	N/A	N/A
3/31/2015	764,671	-8,737	N/A	66,811	N/A
12/31/2014	749,627	39,710	N/A	N/A	N/A
9/30/2014	734,469	43,896	N/A	72,544	N/A
6/30/2014	721,070	23,599	N/A	N/A	N/A
3/31/2014	713,286	13,627	N/A	72,388	N/A
12/31/2013	696,297	6,239	N/A	N/A	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei 7733 ( 14.4% per jaar) ligt boven de spaarquote ( 0.3% ).

Winst versus markt: De winst van 7733 ( 14.4% per jaar) zal naar verwachting sneller groeien dan de JP markt ( 7.9% per jaar).

Hoge groeiwinsten: De winst van 7733 zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van 7733 ( 5.1% per jaar) zal naar verwachting sneller groeien dan de markt JP ( 4.1% per jaar).

Hoge groei-inkomsten: De omzet van 7733 ( 5.1% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 7733 zal naar verwachting over 3 jaar laag zijn ( 16.1 %).

Olympus Toekomstige groei

Future criteriumcontroles 3/6

Belangrijke informatie

Recente toekomstige groei-updates

Olympus Corporation Revises Consolidated Revenue Guidance for the Fiscal Year Ending March 31, 2024

Olympus Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Olympus Corporation Reiterates Consolidated Financial Guidance for the Fiscal Year Ending March 2024

Consensus EPS estimates fall by 38%

Consensus EPS estimates increase by 79%

Consensus EPS estimates fall by 61%

Recent updates

Olympus' (TSE:7733) Strong Earnings Are Of Good Quality

Dividend of JP¥20.00 announced

Second quarter 2025 earnings: EPS misses analyst expectations

Olympus Corporation's (TSE:7733) Share Price Could Signal Some Risk

Olympus Corporation Announces Resignation of Stefan Kaufmann as Chief Executive Officer, Effective October 28, 2024

Olympus (TSE:7733) Hasn't Managed To Accelerate Its Returns

A Look At The Intrinsic Value Of Olympus Corporation (TSE:7733)

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Olympus Corporation Announces Executive Changes, Effective October 1, 2024

High number of new directors

Does Olympus (TSE:7733) Have A Healthy Balance Sheet?

Now 22% overvalued after recent price rise

Estimating The Fair Value Of Olympus Corporation (TSE:7733)

High number of new directors

Olympus Corporation, Annual General Meeting, Jun 26, 2024

Olympus Corporation (TSE:7733) announces an Equity Buyback for 60,000,000 shares, representing 5.15% for ¥100,000 million.

Slowing Rates Of Return At Olympus (TSE:7733) Leave Little Room For Excitement

Olympus Corporation to Report Q1, 2025 Results on Aug 07, 2024

Upcoming dividend of JP¥18.00 per share

Olympus Corporation's (TSE:7733) Share Price Matching Investor Opinion

Dividend of JP¥18.00 announced

Olympus Corporation Revises Consolidated Revenue Guidance for the Fiscal Year Ending March 31, 2024

New minor risk - Earnings quality

Olympus Corporation Announces Executive Changes

Olympus Corporation (TSE:7733) completed the acquisition of Taewoong Medical Co. Ltd. from Kyong-min Shin and others.

Now 21% overvalued after recent price rise

Olympus Corporation Announces Study Results Show the S Sustained Clinical Benefits of Spiration Valve System At 24 Months

Olympus Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Olympus Corporation (TSE:7733) announces an Equity Buyback for 53,000,000 shares, representing 4.34% for ¥80,000 million.

Olympus Corporation Announces Market Launch of EVIS X1 Endoscopy System

Olympus Corporation Announces the Launch of the Vathin E-SteriScope

Investor sentiment deteriorates as stock falls 16%

New minor risk - Share price stability

First quarter 2024 earnings: Revenues and EPS in line with analyst expectations

Olympus Corporation Announces Publication of Study Data Demonstrating That the Minimally Invasive Itind™? Treatment Provides Long-Lasting Relief of More Than Four Years

Olympus Corporation to Report Q3, 2024 Results on Feb 14, 2024

Full year 2023 earnings: EPS misses analyst expectations

Olympus Corporation Reiterates Consolidated Financial Guidance for the Fiscal Year Ending March 2024

Olympus Names Wenlei Yang the Newly Established Chief Diversity, Equity and Inclusion Officer

Full year 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 38%

Olympus Corporation, Annual General Meeting, Jun 27, 2023

Now 21% undervalued after recent price drop

Olympus Corporation Set to Demonstrate Newest Endoscopy System At DDW

Now 21% undervalued

Consensus EPS estimates increase by 79%

Consensus EPS estimates fall by 61%

Upcoming dividend of JP¥16.00 per share at 0.7% yield

Third quarter 2023 earnings released: EPS: JP¥28.43 (vs JP¥19.66 in 3Q 2022)

Olympus Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Consensus forecasts updated

Consensus forecasts updated

Second quarter 2023 earnings released

Second quarter 2023 earnings released

Olympus Corporation (TSE:7733) announces an Equity Buyback for 21,000,000 shares, representing 1.65% for ¥50,000 million.

Olympus Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Olympus Launches VISERA ELITE III Surgical Visualization Platform

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Bain Capital Private Equity, LP entered into a definitive agreement to acquire Scientific Solutions Business of Olympus Corporation from Olympus Corporation (TSE:7733) for approximately JPY 427.67 billion.

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Olympus Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

High number of new directors

Olympus Announces the Availability of New Monitor Option, the OEV321UH Video Display Monitor

Full year 2022 earnings: Revenues in line with analyst expectations

Olympus Corporation Announces Study Results Show Long-Term Efficacy of Itind Procedure

Investor sentiment improved over the past week

Olympus Corporation to Report Q3, 2023 Results on Feb 10, 2023